Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug riliprubart tested for Long-Term control of nerve disease CIDP

NCT ID NCT06859099

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving the drug for up to 3 years to see if it remains safe and effective. The goal is to see if riliprubart can help prevent relapses and manage the disease over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
riliprubart (a drug given as a subcutaneous injection)
What this could lead to
If successful, this could show that riliprubart is a safe and effective long-term treatment option for people with CIDP, potentially reducing relapses and the need for other therapies.
What could go wrong
This is an extension study, so participants already know the drug works for them. It is not a placebo-controlled trial, so results may not apply to all CIDP patients. Long-term side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participants with chronic inflammatory demyelinating polyneuropathy (CIDP) currently receiving riliprubart who completed treatment in Part B of Study PDY16744, Study EFC17236, or Study EFC18156. (Participants receiving riliprubart in Part C of PDY16744 are eligible after completing the Part C End of Treatment visit.) 2. All participants must agree to use contraception methods during and after the study as required. Contraceptive use by men and women participating in the study should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 3. Participant must be capable of giving signed informed consent as described in Appendix 1 of the protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: 1. Pregnancy, defined as a positive result of a highly sensitive urine or serum pregnancy test, or lactation 2. Clinical diagnosis of systemic lupus erythematosus (SLE) 3. History of any hypersensitivity to riliprubart or any of its components, or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody 4. Any country-related specific regulation that would prevent the participant from entering the study 5. Accommodation in an institution because of regulatory or legal order; for instance, a prisoner or participant who is legally institutionalized 6. Unsuitability for participation as judged by the Investigator, whatever the reason, including: medical or clinical condition, potential risk of participant noncompliance with study procedures, or any other clinically significant change in the participants' medical condition The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polyneuropathy, inflammatory demyelinating, chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy polyneuropathy, inflammatory demyelinating, chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polyneuropathy, inflammatory demyelinating, chronic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    59 sites in 24 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alabama Neurology Associates- Site Number : 8400019

    Homewood, Alabama, 35209, United States

  • Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014

    Scottsdale, Arizona, 85251, United States

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760004

    Ribeirão Preto, São Paulo, 14049-900, Brazil

  • Investigational Site Number : 0320003

    Buenos Aires, 1221, Argentina

  • Investigational Site Number : 1000002

    Blagoevgrad, 2700, Bulgaria

  • Investigational Site Number : 1240001

    Gatineau, Quebec, J8Y 1W2, Canada

  • Investigational Site Number : 1240002

    Québec, Quebec, G1E 7G9, Canada

  • Investigational Site Number : 1520002

    Puente Alto, Reg Metropolitana de Santiago, 8207257, Chile

  • Investigational Site Number : 1520003

    Lo Barnechea, Reg Metropolitana de Santiago, 7691236, Chile

  • Investigational Site Number : 1560001

    Shanghai, 200040, China

  • Investigational Site Number : 1560002

    Fuzhou, 350001, China

  • Investigational Site Number : 1560003

    Wuhan, 430030, China

  • Investigational Site Number : 1560005

    Beijing, 100053, China

  • Investigational Site Number : 1560006

    Wuhan, 430060, China

  • Investigational Site Number : 1560009

    Changsha, 410008, China

  • Investigational Site Number : 1560011

    Chengdu, 610072, China

  • Investigational Site Number : 1560012

    Guangzhou, 510000, China

  • Investigational Site Number : 1560013

    Beijing, 100034, China

  • Investigational Site Number : 1560014

    Hangzhou, 310009, China

  • Investigational Site Number : 1580001

    Taipei, 100, Taiwan

  • Investigational Site Number : 2030001

    Prague, 128 08, Czechia

  • Investigational Site Number : 2030004

    Brno, 625 00, Czechia

  • Investigational Site Number : 2080001

    Copenhagen, 2100, Denmark

  • Investigational Site Number : 2080002

    Aarhus, 8200, Denmark

  • Investigational Site Number : 2500001

    Le Kremlin-Bicêtre, 94270, France

  • Investigational Site Number : 2500002

    Marseille, 13885, France

  • Investigational Site Number : 2500004

    Paris, 75013, France

  • Investigational Site Number : 2500005

    Toyama, 939-2716, Japan

  • Investigational Site Number : 2500007

    Bordeaux, 33076, France

  • Investigational Site Number : 2760002

    Göttingen, 37075, Germany

  • Investigational Site Number : 2760003

    Münster, 48149, Germany

  • Investigational Site Number : 2760004

    Tübingen, 72076, Germany

  • Investigational Site Number : 3800001

    Milan, Milano, 20132, Italy

  • Investigational Site Number : 3800002

    Rome, Roma, 00168, Italy

  • Investigational Site Number : 3800003

    Genoa, Genova, 16132, Italy

  • Investigational Site Number : 3800004

    Rozzano, Milano, 20089, Italy

  • Investigational Site Number : 3800005

    Pavia, 27100, Italy

  • Investigational Site Number : 3800007

    Pisa, 56126, Italy

  • Investigational Site Number : 3920011

    Bunkyo-Ku, Tokyo, 113-8510, Japan

  • Investigational Site Number : 3920012

    Higashi-Matsuyama, Saitama, 355-0005, Japan

  • Investigational Site Number : 4100003

    Seoul, Seoul-teukbyeolsi, 02841, South Korea

  • Investigational Site Number : 4840001

    Tlalnepantla, 54055, Mexico

  • Investigational Site Number : 5280001

    Amsterdam, 1105 AZ, Netherlands

  • Investigational Site Number : 6160001

    Lublin, Lublin Voivodeship, 20-954, Poland

  • Investigational Site Number : 6200004

    Lisbon, 1150-199, Portugal

  • Investigational Site Number : 6880001

    Belgrade, 11000, Serbia

  • Investigational Site Number : 7240001

    Barcelona, Catalunya [Cataluña], 08041, Spain

  • Investigational Site Number : 7240002

    Barcelona, Catalunya [Cataluña], 08035, Spain

  • Investigational Site Number : 7240003

    Valencia, 46026, Spain

  • Investigational Site Number : 7240004

    Majadahonda, Madrid, 28222, Spain

  • Investigational Site Number : 7240006

    Pamplona, Navarre, 31008, Spain

  • Investigational Site Number : 7240008

    Málaga, 29010, Spain

  • Investigational Site Number : 7520001

    Stockholm, 113 65, Sweden

  • Investigational Site Number : 7920001

    Istanbul, 34093, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Konya, 42075, Turkey (Türkiye)

  • Investigational Site Number : 8260001

    Oxford, Oxfordshire, OX3 9DU, United Kingdom

  • L2IP - Instituto de Pesquisas Clínicas- Site Number : 0760006

    Brasília, Federal District, 70200-730, Brazil

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022

    Philadelphia, Pennsylvania, 19104, United States

  • University of Kansas Medical Center- Site Number : 8400010

    Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.